281 related articles for article (PubMed ID: 20832248)
1. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes.
Lin PI; Shuldiner AR
Schizophr Res; 2010 Nov; 123(2-3):234-43. PubMed ID: 20832248
[TBL] [Abstract][Full Text] [Related]
2. Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome.
Postolache TT; Del Bosque-Plata L; Jabbour S; Vergare M; Wu R; Gragnoli C
Am J Med Genet B Neuropsychiatr Genet; 2019 Apr; 180(3):186-203. PubMed ID: 30729689
[TBL] [Abstract][Full Text] [Related]
3. Evidence for genetic contribution to the increased risk of type 2 diabetes in schizophrenia.
Hackinger S; Prins B; Mamakou V; Zengini E; Marouli E; Brčić L; Serafetinidis I; Lamnissou K; Kontaxakis V; Dedoussis G; Gonidakis F; Thanopoulou A; Tentolouris N; Tsezou A; Zeggini E
Transl Psychiatry; 2018 Nov; 8(1):252. PubMed ID: 30470734
[TBL] [Abstract][Full Text] [Related]
4. Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis.
Liu Y; Li Z; Zhang M; Deng Y; Yi Z; Shi T
BMC Med Genomics; 2013; 6 Suppl 1(Suppl 1):S17. PubMed ID: 23369358
[TBL] [Abstract][Full Text] [Related]
5. Dopamine-prolactin pathway potentially contributes to the schizophrenia and type 2 diabetes comorbidity.
Gragnoli C; Reeves GM; Reazer J; Postolache TT
Transl Psychiatry; 2016 Apr; 6(4):e785. PubMed ID: 27093067
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study.
Mamakou V; Hackinger S; Zengini E; Tsompanaki E; Marouli E; Serafetinidis I; Prins B; Karabela A; Glezou E; Southam L; Rayner NW; Kuchenbaecker K; Lamnissou K; Kontaxakis V; Dedoussis G; Gonidakis F; Thanopoulou A; Tentolouris N; Zeggini E
BMC Psychiatry; 2018 Aug; 18(1):249. PubMed ID: 30071838
[TBL] [Abstract][Full Text] [Related]
7. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?
Gough SC; O'Donovan MC
J Psychopharmacol; 2005 Nov; 19(6 Suppl):47-55. PubMed ID: 16280337
[TBL] [Abstract][Full Text] [Related]
8. How can genetics help understand the relationship between cognitive dysfunction and schizophrenia?
Smeland OB; Andreassen OA
Scand J Psychol; 2018 Feb; 59(1):26-31. PubMed ID: 29356008
[TBL] [Abstract][Full Text] [Related]
9. Modulation ofTcf7l2 expression alters behavior in mice.
Savic D; Distler MG; Sokoloff G; Shanahan NA; Dulawa SC; Palmer AA; Nobrega MA
PLoS One; 2011; 6(10):e26897. PubMed ID: 22046400
[TBL] [Abstract][Full Text] [Related]
10. Genetic markers of type 2 diabetes: Progress in genome-wide association studies and clinical application for risk prediction.
Wang X; Strizich G; Hu Y; Wang T; Kaplan RC; Qi Q
J Diabetes; 2016 Jan; 8(1):24-35. PubMed ID: 26119161
[TBL] [Abstract][Full Text] [Related]
11. Evidence that the pituitary gland connects type 2 diabetes mellitus and schizophrenia based on large-scale trans-ethnic genetic analyses.
Cai L; Sun Y; Liu Y; Chen W; He L; Wei DQ
J Transl Med; 2022 Nov; 20(1):501. PubMed ID: 36329495
[TBL] [Abstract][Full Text] [Related]
12. Genetic Overlap Between Schizophrenia and Volumes of Hippocampus, Putamen, and Intracranial Volume Indicates Shared Molecular Genetic Mechanisms.
Smeland OB; Wang Y; Frei O; Li W; Hibar DP; Franke B; Bettella F; Witoelar A; Djurovic S; Chen CH; Thompson PM; Dale AM; Andreassen OA
Schizophr Bull; 2018 Jun; 44(4):854-864. PubMed ID: 29136250
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide association studies and type 2 diabetes.
Wheeler E; Barroso I
Brief Funct Genomics; 2011 Mar; 10(2):52-60. PubMed ID: 21436302
[TBL] [Abstract][Full Text] [Related]
14. Novel biological insights emerging from genetic studies of type 2 diabetes and related metabolic traits.
De Silva NM; Frayling TM
Curr Opin Lipidol; 2010 Feb; 21(1):44-50. PubMed ID: 19956073
[TBL] [Abstract][Full Text] [Related]
15. Genetic insight of schizophrenia: past and future perspectives.
Singh S; Kumar A; Agarwal S; Phadke SR; Jaiswal Y
Gene; 2014 Feb; 535(2):97-100. PubMed ID: 24140491
[TBL] [Abstract][Full Text] [Related]
16. Type-2 diabetes-associated variants with cross-trait relevance: Post-GWAs strategies for biological function interpretation.
Frau F; Crowther D; Ruetten H; Allebrandt KV
Mol Genet Metab; 2017 May; 121(1):43-50. PubMed ID: 28385534
[TBL] [Abstract][Full Text] [Related]
17. Integrating genome-wide association study and methylation functional annotation data identified candidate genes and pathways for schizophrenia.
Qi X; Guan F; Wen Y; Li P; Ma M; Cheng S; Zhang L; Liang C; Cheng B; Zhang F
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jan; 96():109736. PubMed ID: 31425724
[TBL] [Abstract][Full Text] [Related]
18. Identification of Common Pathogenetic Processes between Schizophrenia and Diabetes Mellitus by Systems Biology Analysis.
Rahman MR; Islam T; Nicoletti F; Petralia MC; Ciurleo R; Fisicaro F; Pennisi M; Bramanti A; Demirtas TY; Gov E; Islam MR; Mussa BM; Moni MA; Fagone P
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33562405
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of shared genetic susceptibility loci between autoimmune diseases and schizophrenia based on genome-wide association studies.
Hoeffding LK; Rosengren A; Thygesen JH; Schmock H; Werge T; Hansen T
Nord J Psychiatry; 2017 Jan; 71(1):20-25. PubMed ID: 27348781
[TBL] [Abstract][Full Text] [Related]
20. Exploring Lead loci shared between schizophrenia and Cardiometabolic traits.
He Q; Bennett AN; Liu J; Fan B; Han X; Cheng L; Chen Y; Yang X; Chan KHK
BMC Genomics; 2022 Aug; 23(1):617. PubMed ID: 36008755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
